Shares of Gossamer Bio are experiencing a sharp increase today. The surge comes amid reports that the biotech company is in discussions regarding several key corporate updates.
According to reports, Gossamer Bio is discussing the potential reacquisition of rights to Seralutinib, a drug candidate. The company is also reportedly reviewing its regulatory progress and considering updates to its capital structure.
The details of these discussions remain unconfirmed, and no official statements have been released by the company at this time.